Royce & Associates LP Increases Stock Position in Enfusion, Inc. (NYSE:ENFN)

Royce & Associates LP lifted its stake in Enfusion, Inc. (NYSE:ENFN) by 84.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 184,078 shares of the company’s stock after acquiring an additional 84,363 shares during the quarter. Royce & Associates LP owned 0.14% of Enfusion worth $1,896,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in ENFN. Paloma Partners Management Co bought a new position in Enfusion in the third quarter valued at about $157,000. Centiva Capital LP lifted its stake in shares of Enfusion by 5.0% in the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after purchasing an additional 1,227 shares during the period. Azora Capital LP lifted its stake in shares of Enfusion by 6.8% in the 3rd quarter. Azora Capital LP now owns 29,827 shares of the company’s stock worth $283,000 after purchasing an additional 1,890 shares during the period. Quest Partners LLC purchased a new position in shares of Enfusion in the third quarter worth approximately $308,000. Finally, Rhumbline Advisers grew its position in Enfusion by 3.0% during the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after buying an additional 1,796 shares during the period. 81.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Enfusion

In other Enfusion news, COO Neal Pawar sold 14,560 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $165,692.80. Following the sale, the chief operating officer now owns 1,217,067 shares in the company, valued at $13,850,222.46. The trade was a 1.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bronwen Bastone sold 3,126 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total transaction of $35,573.88. Following the transaction, the insider now directly owns 221,875 shares of the company’s stock, valued at $2,524,937.50. This trade represents a 1.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 77,346 shares of company stock valued at $868,109 over the last 90 days. Company insiders own 36.44% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Piper Sandler increased their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. Stifel Nicolaus raised their target price on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Finally, William Blair reissued a “market perform” rating on shares of Enfusion in a report on Monday, January 13th.

Enfusion Price Performance

Shares of NYSE:ENFN opened at $11.11 on Friday. The company has a market capitalization of $1.43 billion, a P/E ratio of 277.69, a P/E/G ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 1-year low of $7.83 and a 1-year high of $11.80. The firm’s 50 day simple moving average is $11.13 and its two-hundred day simple moving average is $10.06.

Enfusion (NYSE:ENFN) last released its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The firm had revenue of $52.94 million for the quarter, compared to analysts’ expectations of $53.98 million. On average, sell-side analysts anticipate that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.